Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk, joins BNN Bloomberg to discuss the runaway success of the company's Ozempic and Wegovy drugs, that treat diabetes and obesity, respectively. Mr Jørgensen says there is very strong momentum in their business, and they are working hard to get some of their medicines to more markets such as Canada because there's a huge need. He also describes the partnerships Novo Nordisk has with the University of Toronto and the city of Mississauga.